Article Text

Download PDFPDF

Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
  1. Heinrich Gerding1,2,
  2. Jordi Monés3,
  3. Ramin Tadayoni4,
  4. Francesco Boscia5,
  5. Ian Pearce6,
  6. Siegfried Priglinger7
  1. 1Augenzentrum Klinik Pallas, Olten, Switzerland
  2. 2Department of Ophthalmology, University of Muenster, Muenster, Germany
  3. 3Institut de la Màcula i de la Retina, Centro Médico Teknon and Barcelona Macula Foundation, Barcelona, Spain
  4. 4Department of Ophthalmology, Hôpital Lariboisière, Université Paris Diderot—Sorbonne Paris Cité, AP-HP, Paris, France
  5. 5Department of Ophthalmology, University of Sassari, Sassari, Italy
  6. 6St Paul's Eye Unit, Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK
  7. 7Department of Ophthalmology, General Hospital (AKH), Linz, Austria
  1. Correspondence to Professor Heinrich Gerding, Augenzentrum Klinik Pallas, Louis Giroud-Strasse 20, CH-4600 Olten, Switzerland; heinrich.gerding{at}


Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment of macular oedema in RVO and, in 2011, ranibizumab was approved in the European Union for the treatment of visual impairment caused by macular oedema secondary to RVO in branch and central RVO. Ranibizumab provides an additional therapeutic option for this complex disease: an option that was not fully considered during the preparation of current international guidelines. An expert panel was convened to critically evaluate the evidence for treatment with ranibizumab in patients with visual impairment caused by macular oedema secondary to RVO and to develop treatment recommendations, with the aim of assisting physicians to optimise patient treatment.

  • Macula
  • Retina

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

View Full Text

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.